尊龙凯时·人生就是搏(中国区)官方网站

2020-12-14

Sunshine Guojian Selects Verseau’s VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

Early data in patient-derived primary tumors suggest that VSIG4 antibodies could generate a greater anti-tumor inflammatory response compared to current immunotherapies in both PD-1 responsive and non-responsive tumors.

2020-06-28

Sunshine Guojian obtained clinical trial approval by the FDA for the anti-IL-4Rα monoclonal antibody

2020-06-19

Breaking the monopoly of imported anti-HER2 monoclonal antibody drugs Approval obtained for “Inetetamab”, the first innovative anti-HER2 monoclonal antibody independently developed in China

2020-04-28

YISAIPU Wins at the 1st Shanghai Intellectual Property Innovation Award

2020-04-17

Sunshine Guojian Awarded the 2019 Grade A Quality Credit Unit among Shanghai Pharmaceutical Manufacturing Enterprises

Recently, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (referred to as “Sunshine Guojian”) was awarded the Grade A Quality Credit Unit in the 2019 quality credit rating assessment of Shanghai pharmaceutical manufacturing enterprises after a series of strict and comprehensive reviews and assessments.

2020-03-11

Sunshine Guojian Obtains Marketing Authorization of YISAIPU in Indonesia

YISAIPU, an antibody drug independently developed by Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd., a subsidiary of 3SBio,